<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/946B0602-8D02-4119-B979-04EE8CA4C8E8"><gtr:id>946B0602-8D02-4119-B979-04EE8CA4C8E8</gtr:id><gtr:name>ElectroCore LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6DB08663-5F52-4E8C-9D92-3D4FF7D769AB"><gtr:id>6DB08663-5F52-4E8C-9D92-3D4FF7D769AB</gtr:id><gtr:name>Heptares Therapeutics Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63B69DF4-E48C-46C5-B1F8-1EAF5FEEAE39"><gtr:id>63B69DF4-E48C-46C5-B1F8-1EAF5FEEAE39</gtr:id><gtr:name>Mentis Cura</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30CB640-027D-4603-9D2E-9A960744B123"><gtr:id>E30CB640-027D-4603-9D2E-9A960744B123</gtr:id><gtr:name>Autifony Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAA623C1-3BA1-4561-8942-0EFE5069C974"><gtr:id>DAA623C1-3BA1-4561-8942-0EFE5069C974</gtr:id><gtr:name>Nascient ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CE54083-350A-4B6D-A169-F07476A5A7B6"><gtr:id>2CE54083-350A-4B6D-A169-F07476A5A7B6</gtr:id><gtr:name>Neuroelectrics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F19AB1A4-446C-47B6-957D-13C2AF19B798"><gtr:id>F19AB1A4-446C-47B6-957D-13C2AF19B798</gtr:id><gtr:name>CellCap Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/946B0602-8D02-4119-B979-04EE8CA4C8E8"><gtr:id>946B0602-8D02-4119-B979-04EE8CA4C8E8</gtr:id><gtr:name>ElectroCore LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6DB08663-5F52-4E8C-9D92-3D4FF7D769AB"><gtr:id>6DB08663-5F52-4E8C-9D92-3D4FF7D769AB</gtr:id><gtr:name>Heptares Therapeutics Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63B69DF4-E48C-46C5-B1F8-1EAF5FEEAE39"><gtr:id>63B69DF4-E48C-46C5-B1F8-1EAF5FEEAE39</gtr:id><gtr:name>Mentis Cura</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30CB640-027D-4603-9D2E-9A960744B123"><gtr:id>E30CB640-027D-4603-9D2E-9A960744B123</gtr:id><gtr:name>Autifony Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAA623C1-3BA1-4561-8942-0EFE5069C974"><gtr:id>DAA623C1-3BA1-4561-8942-0EFE5069C974</gtr:id><gtr:name>Nascient ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CE54083-350A-4B6D-A169-F07476A5A7B6"><gtr:id>2CE54083-350A-4B6D-A169-F07476A5A7B6</gtr:id><gtr:name>Neuroelectrics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F19AB1A4-446C-47B6-957D-13C2AF19B798"><gtr:id>F19AB1A4-446C-47B6-957D-13C2AF19B798</gtr:id><gtr:name>CellCap Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E5421327-94FD-491C-A2F1-7A24526F6C52"><gtr:id>E5421327-94FD-491C-A2F1-7A24526F6C52</gtr:id><gtr:firstName>Nick J.</gtr:firstName><gtr:surname>Reynolds</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14119"><gtr:id>C96B2513-D946-40BF-AA17-4C4142FEFB45</gtr:id><gtr:title>Translating ?Translation? ? bridging the third translational gap</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14119</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.&amp;nbsp; The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers? understanding of each other?s needs and capabilities.&amp;nbsp; This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ?entrepreneurs in residence? schemes.&amp;nbsp; Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nascient ltd</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop</gtr:description><gtr:id>FB9B7FFD-BD7E-43BC-821D-702AEC505B4D</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e167bd6968d9.07170540-6</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eisai Ltd</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:id>CBA7B87F-DDAE-4476-96C2-A69FB11D9093</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e1666a80a1b7.70174483-2</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop</gtr:description><gtr:id>A656DF99-44F6-4BA5-9162-8821A12A969B</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e167bd6968d9.07170540-5</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AbbVie</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop</gtr:description><gtr:id>1AF2B12B-D59D-4034-9739-EBCA8B4A0969</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e167bd6968d9.07170540-2</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ElectroCore LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:id>BC2A9879-1105-49F7-A78D-39D9AB566424</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e1666a80a1b7.70174483-1</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop</gtr:description><gtr:id>06986FAA-02B5-42DF-9EBD-E4AAD6D8D04A</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e167bd6968d9.07170540-3</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CellCap Technologies</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:id>D61492FB-B08C-404F-A255-04619AB594AB</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e1666a80a1b7.70174483-5</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heptares Therapeutics Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:id>2F2F40B5-8180-4642-B1E7-A842A2175469</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e1666a80a1b7.70174483-7</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Neuroelectrics</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:id>26301739-415D-468E-A41F-74491DDD7DC8</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e1666a80a1b7.70174483-6</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop</gtr:description><gtr:id>0A3DDB73-F2DE-4EDE-A3CD-7BD660D13041</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e167bd6968d9.07170540-4</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mentis Cura</gtr:collaboratingOrganisation><gtr:country>Iceland, Republic of</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:id>733B2C8A-67D6-4C0A-ADC6-8A1D6B6B6FC6</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e1666a80a1b7.70174483-3</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Autifony Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:id>2710A80C-FACA-420A-9F7F-AB68232163BD</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e1666a80a1b7.70174483-4</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop</gtr:description><gtr:id>AC950475-46CD-4214-9297-047738FA2F8E</gtr:id><gtr:impact>Areas of overlap and potential collaborative ventures were identified as a consequence of the workshop. Two way CDAs in place/drafted to initiative further discussion.</gtr:impact><gtr:outcomeId>56e167bd6968d9.07170540-1</gtr:outcomeId><gtr:partnerContribution>Partners engaged with the process enthusiastically and contributed to the debate. Very positive formal feedback received with constructive suggestions.</gtr:partnerContribution><gtr:piContribution>Further details provided under Engagement Activities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Engaging with SMEs for drug repurposing in rare diseases</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AEE1058F-A67A-4E30-B002-FCC9F43E5371</gtr:id><gtr:impact>This is an activity in the planning phase only.</gtr:impact><gtr:outcomeId>56e171a71832e5.64429639</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Proximity to Discovery (PtD): Workshop - Lewy Body Dementia: 'A View from the Bridge'</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E075FDEC-485D-48B3-846A-97D6D0CD8228</gtr:id><gtr:impact>Themed seminars: short, problem focussed, used to highlight to attendees the current state of play in the field. Topics covered, but not limited to, will include: 'Designing clinical trials in Prodromal DLB'; 'Crash course in Lewy body pathology and opportunities for treatment'; 'What biomarkers do we have in early Lewy body dementia?'; 
Clinical demonstrations: histories from patient and carer volunteers to demonstrate clinical signs that typify LBD; representing areas of unmet therapeutic need and hence also market opportunities.
Meeting patients and their carers: in order to allow 'real time' exploration of symptoms and problems that really matter to the person with LBD and their families, to highlight the clinical impact of these conditions.
Demonstration of facilities: guided tours in small groups to demonstrate expertise and capability in areas such as human movement science, neurophysiology, image analysis, basic science laboratories and brain tissue resource / neuropathology.
Individual meetings with Lewy body dementia investigators covering symptom targets, animal models, biomarker development, and clinical trial support will also be included.

The audience (industry visitors) greatly appreciated the opportunity to discuss specific topics in small groups. Some have expressed a wish to collaborate further in future.</gtr:impact><gtr:outcomeId>56e15ffa3144a4.11124962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.newcastleptd.com/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regulatory requirements of medical and in vitro/ex vivo diagnostics devices</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B8EF3E38-9779-43AA-B311-8515A0C072C5</gtr:id><gtr:impact>A half-day workshop delivered by an external medical device consultant and open to researchers from across FMS and SAgE with an interest in developing medical devices and understanding more about MHRA, CE marking and EU registration of medical devices. A more focussed 1.5 days of individual project development time between the consultant (Dr Keith Morris), researchers and Reece Innovation, based around specific devices already under development.
As a consequence of this award Professor Baker and Dr Baker have been able to submit an MRC DPFS application for developing an electrodiagnostic device with Reece Innovation as a MICA partner. On the strength of the outline application, Dr Baker and Professor Baker have been invited to submit a full application.</gtr:impact><gtr:outcomeId>58c7ea5823d145.57565718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Proximity to Discovery (PtD): Dermatology/Rheumatology workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>100F3D33-D416-473F-8AA1-2B5F5FCE3576</gtr:id><gtr:impact>Dermatology activities included:
Themed seminars including but not limited to systems biology approaches to psoriasis therapy, biomarkers of melanoma progression, topical treatment of non-melanoma skin cancer.
Individual meetings with dermatological investigators covering psoriasis and biologics, atopic eczema, metastatic melanoma, phototherapy, connective diseases, open discussion of clinical unmet need and potential for novel therapeutic targets, open discussion of access to UK dermatological scientific and clinical community through UK TREND (http://www.uktrend.org/) and other networks.

Rheumatology activities for the theme week included:
Themed seminars including but not limited to inflammatory arthritis (including rheumatoid arthritis, spondyloarthropathy), osteoarthritis, Sj&amp;ouml;gren's syndrome, biomarkers and immune modulation.
Individual meetings with rheumatology investigators covering early arthritis, resistant arthritis, Sjogren's syndrome, juvenile idiopathicarthritis, Spondyloarthropathy and connective tissue disease.
In both cases activities included round-table discussion, one-to-one sessions, social gatherings and meetings with local patient groups.</gtr:impact><gtr:outcomeId>56e1621357f012.40173876</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.newcastleptd.com/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>0</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newcastle/Genentech collaboration</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Genentech</gtr:fundingOrg><gtr:fundingRef>Contract in final stages of negotiation contract amount is commercially sensitive information</gtr:fundingRef><gtr:id>9BAF6A6A-DC69-48A3-A996-6F337B945A2E</gtr:id><gtr:outcomeId>58c7f1946542d3.56333607</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14119</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>